10x Genomics price target lowered to $18 from $21 at Stifel

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment uncertainty clouds the 2025 view, but at $12 per share, 10x Genomics has “quite a few challenges baked into the stock” price, says the analyst. However, it is “fair to assume that operating environment clarity will be needed for most,” the analyst added in a post-earnings and guidance note.